ArticlemSphere2020
Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.
Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Pooled it
- Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis.International immunopharmacology · 2021Pooled it
- Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.The Journal of clinical investigation · 2022Trial
- Impact of Gestational Maternal SARS-CoV-2 Infection on Neonatal Inflammatory Biomarkers.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- Helping alveolar macrophages live to fight another day during viral pneumonia.The Journal of clinical investigation · 2026Article
- TNF superfamily member 14 drives post-influenza depletion of alveolar macrophages, enabling secondary pneumococcal pneumonia.The Journal of clinical investigation · 2026Article
- Impact of Gestational Maternal SARS-CoV-2 Infection on Neonatal Inflammatory Biomarkers.Research square · 2025Article
- Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.Nature reviews. Drug discovery · 2024Review
- Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis Patients.Biomedicines · 2024Article
- A case of chronic kidney disease patient with rapid deterioration of renal function, hair loss, and spontaneous resolution of facial warts after COVID-19 infection.Aging medicine (Milton (N.S.W)) · 2024Article
- LIGHT/TNFSF14 Affects Adipose Tissue Phenotype.International journal of molecular sciences · 2024Article
- Investigation of SARS-CoV-2 individual proteins reveals the in vitro and in vivo immunogenicity of membrane protein.Scientific reports · 2023Article
- COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023Article
- Research Progress of DcR3 in the Diagnosis and Treatment of Sepsis.International journal of molecular sciences · 2023Review
- Obesity Is Associated with Attenuated Tissue Immunity in COVID-19.American journal of respiratory and critical care medicine · 2023Article
- Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease.Life (Basel, Switzerland) · 2023Review
- Identifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapy.Frontiers in immunology · 2023Article
- Realigning the LIGHT signaling network to control dysregulated inflammation.The Journal of experimental medicine · 2022Article
- COVID-19 therapeutics: Challenges and directions for the future.Proceedings of the National Academy of Sciences of the United States of America · 2022Review
- Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many coronavirus disease 2019 (COVID-19) patients demonstrate lethal respiratory complications caused by cytokine release syndrome (CRS). Multiple cytokines have been implicated in CRS, but levels of tumor necrosis factor superfamily 14 (TNFSF14) (LIGHT) have not been previously measured in this setting. In this study, we observed significantly elevated serum LIGHT levels in hospitalized COVID-19 patients compared to healthy age- and gender-matched control patients. The assay detected bioavailable LIGHT unbound to the inhibitor Decoy receptor-3 (DcR3). Bioavailable LIGHT levels were elevated in patients both on and off ventilatory support, with a trend toward higher levels in patients requiring mechanical ventilation. In hospitalized patients over the age of 60, who exhibited a mortality rate of 82%, LIGHT levels were significantly higher (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.